

## Efficacy and Safety of Immunotherapies for the Treatment of Alzheimer's Disease: A Network Meta-Analysis

**Rida Rabab Chowdhury**

Submitted to International Medical University, Fulfillment of the Requirements, Degree of Bachelor's in Medical Sciences (Hons)

**Igor Nikolayevich Iezhitsa**

Re-submission Submitted to International Medical University, Fulfillment of the Requirements, Degree of Bachelor's in Medical Sciences (Hons)

### Abstract:

**Background:** Alzheimer's disease (AD) is a progressive neurodegenerative disorder regarded as the most prevalent cause of dementia, particularly amongst the aging population. AD contributes to 60–70% of cases with there being over 10 million new cases of dementia each year worldwide.

Unfortunately, currently, available treatments for AD can only limit the symptoms of cognitive impairment. Due to this, the focus for AD treatment incorporates addressing, limiting and potentially halting the pathogenesis of amyloid-beta ( $A\beta$ ) and the accumulation of abnormal tau protein in the brain, altogether. However, the safety and efficacy of this treatment regime must be collated to ensure its clinical use in improving the livelihood of AD patients.